NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis $2.01 -0.04 (-1.95%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About TherapeuticsMD Stock (NASDAQ:TXMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TherapeuticsMD alerts:Sign Up Key Stats Today's Range$2.01▼$2.0850-Day Range$2.01▼$2.2852-Week Range$0.99▼$2.95Volume19,380 shsAverage Volume45,593 shsMarket Capitalization$23.26 millionP/E Ratio100.50Dividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview TherapeuticsMD, Inc. was a pharmaceutical company focused on developing and commercializing products for women’s health. The company’s portfolio addressed contraception, menopause, and related reproductive-health needs, primarily in the United States. Its principal products included ANNOVERA, a reusable vaginal contraceptive system; IMVEXXY, a vaginal estradiol insert for treating moderate-to-severe dyspareunia associated with menopause; and BIJUVA, an oral hormone therapy containing estradiol and progesterone for certain menopausal symptoms. TherapeuticsMD also developed prenatal vitamins and other products intended to support women’s health. TherapeuticsMD was formerly publicly traded on the Nasdaq under the symbol TXMD. The company later underwent significant financial and strategic changes, including a bankruptcy restructuring and the transfer or sale of rights to certain products. Accordingly, its historical product portfolio and corporate status may differ from information associated with the former public company.AI Generated. May Contain Errors. Read More TherapeuticsMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreTXMD MarketRank™: TherapeuticsMD scored higher than 11% of companies evaluated by MarketBeat, and ranked 839th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingTherapeuticsMD has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTherapeuticsMD has only been the subject of 1 research reports in the past 90 days.Read more about TherapeuticsMD's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of TherapeuticsMD is 104.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.95.Price to Earnings Ratio vs. SectorThe P/E ratio of TherapeuticsMD is 104.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.85.Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TherapeuticsMD's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.23% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 1.27, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently increased by 0.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of TherapeuticsMD is held by insiders.Percentage Held by Institutions30.74% of the stock of TherapeuticsMD is held by institutions.Read more about TherapeuticsMD's insider trading history. Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TXMD Stock News HeadlinesCritical Comparison: Tilray Brands (NASDAQ:TLRY) & TherapeuticsMD (NASDAQ:TXMD)October 5 at 8:14 AM | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) and Shineco (NASDAQ:SISI) Head to Head AnalysisOctober 5 at 5:44 AM | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 5 at 1:00 AM | Porter & Company (Ad)TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gainsJune 5, 2026 | marketwatch.comTherapeuticsMD Reports Quarterly Profit, Evaluates Strategic AlternativesMay 12, 2026 | tipranks.comTherapeuticsMD Announces First Quarter 2026 Financial ResultsMay 12, 2026 | businesswire.comTherapeuticsMD Inc. stock outperforms competitors on strong trading dayApril 6, 2026 | marketwatch.comTherapeuticsMD Narrows 2025 Loss, Advances Royalty StrategyApril 2, 2026 | theglobeandmail.comSee More Headlines TXMD Stock Analysis - Frequently Asked Questions How have TXMD shares performed this year? TherapeuticsMD's stock was trading at $1.63 on January 1st, 2026. Since then, TXMD shares have increased by 27.6% and is now trading at $2.08. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) posted its earnings results on Tuesday, August, 11th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($6.13) by $6.14. The company had revenue of $0.87 million for the quarter, compared to analysts' expectations of $19.77 million. TherapeuticsMD had a negative trailing twelve-month return on equity of 1.09% and a negative net margin of 6.64%. When did TherapeuticsMD's stock split? TherapeuticsMD shares reverse split on Monday, May 9th 2022.The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), AUO (AUOTY) and The RMR Group (RMR). Company Calendar Last Earnings8/11/2026Today10/05/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TXMD's financial health is in the Green zone, according to TradeSmith. TXMD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees420Year Founded2008Profitability EPS (Trailing Twelve Months)$0.02 Trailing P/E Ratio100.50 Forward P/E RatioN/A P/E GrowthN/ANet Income-$570 thousand Net Margins-6.64% Pretax Margin-8.04% Return on Equity-1.09% Return on Assets-0.78% Debt Debt-to-Equity RatioN/A Current Ratio3.22 Quick Ratio3.22 Sales & Book Value Annual Sales$3.02 million Price / Sales7.70 Cash Flow$0.05 per share Price / Cash Flow43.94 Book Value$2.32 per share Price / Book0.87Miscellaneous Outstanding Shares11,570,000Free Float11,377,000Market Cap$23.26 million OptionableOptionable Beta0.65 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TXMD) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
